Skip to content

International Delivery — £35 per Order

Home/Learn/Tirzepatide
Back to Learn Hub
Peptide Guide

Tirzepatide (Dual GLP-1/GIP Receptor Agonist)

Category: GLP-1 Agonists

Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Developed by Eli Lilly, it represents a fundamentally different approach from single-receptor agonists like semaglutide. By activating both incretin pathways simultaneously, it produces effects that neither pathway achieves alone.

This guide compiles key literature themes, handling context, and practical comparison points for research-focused evaluation.

By Maylene · Page updated

Overview

The clinical data has been striking. In the SURMOUNT-1 trial, participants lost an average of 22.5% body weight in the top treatment arm, numbers that were previously thought achievable only through surgery. This sparked enormous scientific interest in the concept of dual-receptor targeting.

Discovery & Background

Eli Lilly began developing tirzepatide based on emerging research showing that GIP and GLP-1 receptors have complementary effects on metabolism. The compound received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. The development timeline was accelerated by the dramatic results from early-phase trials, which exceeded expectations for both glycemic control and weight reduction.

Mechanism of Action

Tirzepatide activates both GLP-1 and GIP receptors, creating a synergistic effect on metabolism, appetite regulation, and insulin signaling that single-target compounds cannot replicate.

  • 1
    Binds to and activates GLP-1 receptors with similar potency to native GLP-1, stimulating insulin secretion
  • 2
    Simultaneously activates GIP receptors, which enhances insulin response and may improve fat metabolism
  • 3
    The dual mechanism produces greater appetite suppression than GLP-1 activation alone
  • 4
    GIP receptor activation may counteract some GLP-1-mediated nausea through central mechanisms
  • 5
    Improves insulin sensitivity in adipose tissue through GIP-mediated pathways
  • 6
    A C20 fatty diacid moiety binds to serum albumin, extending the half-life

Research Benefits

The benefit areas below reflect commonly discussed research interests for this peptide.

Superior Weight Reduction

SURMOUNT-1 demonstrated 22.5% average weight loss at the 15mg dose, exceeding results seen with any single-target GLP-1 agonist in clinical trials.

Glycemic Control

SURPASS trials showed HbA1c reductions of up to 2.58%, with over 97% of participants reaching HbA1c below 7%.

Dual Mechanism

The combined GLP-1/GIP activation provides metabolic benefits that neither pathway delivers in isolation.

Improved Tolerability

Some researchers hypothesize the GIP component may partially offset GLP-1-related gastrointestinal side effects.

Reported Side Effects & Considerations

  • •Gastrointestinal symptoms (nausea, diarrhea, decreased appetite) reported in 30-50% of participants in the higher treatment arms
  • •Injection site reactions reported in a small percentage of trial participants
  • •Rare cases of pancreatitis observed, similar to GLP-1 agonist class
  • •Thyroid C-cell tumor risk warning based on rodent studies (not confirmed in humans)

Storage Guidelines

Temperature

As printed on the pen label and stated in its product documentation

Frequently Asked Questions

What makes tirzepatide different from semaglutide?

Tirzepatide activates both GLP-1 and GIP receptors (dual agonist), while semaglutide only activates GLP-1 receptors. This dual mechanism appears to produce greater metabolic effects in clinical trials.

What were the weight loss results in clinical trials?

In SURMOUNT-1, participants in the top treatment arm lost an average of 22.5% body weight over 72 weeks. About one-third of participants lost 25% or more of their body weight.

What is the GIP receptor?

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances insulin secretion and influences fat metabolism. Its receptor is found in the pancreas, brain, adipose tissue, and other organs.

Has tirzepatide been compared directly to semaglutide?

Yes, the SURPASS-2 trial compared tirzepatide with the diabetes strength of semaglutide and found tirzepatide superior in both glycemic control and weight loss.

Sources & evidence

Maylene research library

These papers describe the stated compounds and study models. They do not test or certify Maylene products. Animal or cell findings do not establish human benefit, and pharmaceutical trials do not validate research-only pens.

Editorial approach and corrections

Research Disclaimer

This guide is for educational and informational purposes only. All information is based on published scientific research and peer-reviewed literature. Peptides sold by Maylene are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.

Shop Tirzepatide

Check the current catalogue for this compound and review any matching batch documentation.

Review variant options and quantity pricing before adding to cart.

View TirzepatideBrowse All Peptides

Explore More Peptide Guides

Explore adjacent compounds to compare mechanisms, side-effect discussions, and study focus across related peptides.

Start Your Research Today

Compare current listings, labelled content and product documentation before ordering.

Products from Maylene are supplied strictly for laboratory and scientific research use only.

Shop Peptides